ESMO/X
Aug 8, 2025, 14:19
How does ESMO-MCBS v2.0 Reflect the Evolving Oncology Treatment Landscape?
European Society for Medical Oncology (ESMO) shared a post on X:
“How does ESMO-MCBS v2.0 reflect the evolving oncology treatment landscape and the priorities of Patients With Cancer? Sjoukje Oosting shares her insights in the ESMO Daily Reporter.”
Title: ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)
Authors: N.I. Cherny, S.F. Oosting, U. Dafni, N.J. Latino, M. Galotti, P. Zygoura, G. Dimopoulou, T. Amaral, J. Barriuso, A. Calles, B. Kiesewetter, C. Gomez-Roca, B. Gyawali, M. Piccart, A. Passaro, F. Roitberg, N. Tarazona, D. Trapani, G. Curigliano, R. Wester, G. Zarkavelis, C. Zielinski, E.G.E. de Vries.
You can read the Full Article in Annals of Oncology.
More posts featuring ESMO.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 8, 2025, 17:21
Aug 8, 2025, 17:21
Aug 8, 2025, 16:46
Aug 8, 2025, 16:41
Aug 8, 2025, 16:31
Aug 8, 2025, 16:11
Aug 8, 2025, 15:57
Aug 8, 2025, 15:54
Aug 8, 2025, 15:49